Key result
Interatrial block independently predicted the primary composite endpoint of new-onset atrial fibrillation, death, or heart transplant in CRT recipients (HR 1.9; 95% CI 1.2-2.9; p=0.004).
Why the study?
The prognostic importance of interatrial block and abnormal P-wave terminal force in lead V1 regarding new-onset AF and death had not been proven in CRT recipients.
Does the presence of interatrial block or abnormal PTFV1 predict new-onset atrial fibrillation, death, or heart transplant in CRT recipients?
Cohort (n=210)
Does the presence of interatrial block or abnormal PTFV1 predict new-onset atrial fibrillation, death, or heart transplant in CRT recipients?
Interatrial block is a significant predictor of new-onset atrial fibrillation, death, or heart transplant in CRT recipients, offering a potential tool for risk stratification in heart failure management.
Background: Interatrial block (IAB) and abnormal P-wave terminal force in lead V₁ (PTFV₁) are electrocardiographic (ECG) abnormalities that have been shown to be associated with new-onset atrial fibrillation (AF) and death. However, their prognostic importance has not been proven in cardiac resynchronization therapy (CRT) recipients. Objective: To assess if IAB and abnormal PTFV₁ are associated with new-onset AF or death in CRT recipients. Methods: CRT recipients with sinus rhythm ECG at CRT implantation and no AF history were included (n = 210). Automated analysis of P-wave duration (PWD) and morphology classified patients as having either no IAB (PWD <120 ms), partial IAB (pIAB: PWD ≥120 ms, positive P waves in leads II and aVF), or advanced IAB (aIAB: PWD ≥120 ms and biphasic or negative P wave in leads II or aVF). PTFV₁ >0.04 mm•s was considered abnormal. Adjusted Cox regression analyses were performed to assess the impact of IAB and abnormal PTFV₁ on the primary endpoint new-onset AF, death, or heart transplant (HTx) and the secondary endpoint death or HTx at 5 years of follow-up. Results: IAB was found in 45% of all patients and independently predicted the primary endpoint with HR 1.9 (95% CI 1.2–2.9, p = 0.004) and the secondary endpoint with HR 2.1 (95% CI 1.2–3.4, p = 0.006). Abnormal PTFV₁ was not associated with the endpoints. Conclusions: IAB is associated with new-onset AF and death in CRT recipients and may be helpful in the risk stratification in the context of heart failure management. Abnormal PTFV₁ did not demonstrate any prognostic value.
No takes yet. Share an insight, caveat, or question.
Jacobsson et al. (2020) conducted a cohort in Cardiac resynchronization therapy (CRT) recipients (n=210). Interatrial block (IAB) vs. No IAB was evaluated on new-onset AF, death, or heart transplant (HTx) (HR 1.9, 95% CI 1.2-2.9, p=0.004). Interatrial block independently predicted the primary composite endpoint of new-onset atrial fibrillation, death, or heart transplant in CRT recipients (HR 1.9; 95% CI 1.2-2.9; p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: